| HOME >> BIOLOGY >> TECHNOLOGY |
TITLE: An anticancer C-Kit kinase inhibitor is reengineered to it more active and less cardiotoxic
AUTHOR CONTACT:
Ariel Fernndez
Rice University, Houston, Texas, USA.
Phone: (713) 348-3681; Fax: (713) 348-3699; E-mail: arifer@rice.edu.
MEDIA CONTACT:
Jade C. Boyd
Associate Director of News & Media Relations
Rice University, Houston, Texas, USA.
Phone: (713) 348-6778; E-mail: jadeboyd@rice.edu.
View the PDF of this article at: https://www.the-jci.org/article.php?id=32373
ACCOMPANYING COMMENTARY
TITLE: Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
AUTHOR CONTACT:
George D. Demetri
Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Phone: (617) 632-3985; Fax: (617) 632-3408; E-mail: gdemetri@partners.org.
View the PDF of this article at: https://www.the-jci.org/article.php?id=34252
EDITOR'S PICK: Giving asthma T(he)SL(i)P by blocking OX40
Inflammatory disorders such as asthma and eczema are overzealous immune responses by the body to otherwise innocuous environmental conditions. The protein TSLP is a potent activator of the allergic inflammatory response, and a new report by Flavius Martin and colleagues at Genentech Inc., San Francisco, has identified a role for another protein, OX40, in TSLP-induced allergic reactions in mice and monkeys. As indicated by the authors and Yui-Hsi Wang and Yong-Jun Liu from The University of Texas MD Anderson Cancer Center, Houston, in an accompanying comment
'/>"/>
| Contact: Karen Honey press_releases@the-jci.org 215-573-1850 Journal of Clinical Investigation Source:Eurekalert |